Global human vaccines market set to reach $19.2B by 2010

Driven by technology and globalization moves, the global human vaccines market is forecast to reach $19.2 billion by 2010. Key growth propellers for the vaccines market include the development of new therapeutic and prophylactic agents for combating HIV, severe acute respiratory syndrome and cancer, apart from other fatal diseases, according to a new report from USA-based Global Industry Analysts Inc.

Although prophylactic vaccines remain the biggest earners in the human vaccines market, therapeutic ones in the pipeline could spring major surprises in the years ahead. The global prophylactic vaccines market is estimated at $11.6 billion for 2007. Although accounting for a meager share, the therapeutic vaccines market is expected to record the fastest growth, garnering sales worth $3.3 billion by 2010, says the report.

The USA represents the largest market for human vaccines, with turnover estimated at $6.9 billion for 2007. In Europe, France, Germany and the UK together account for more than 75% of the market. In Japan, pediatric prophylactic vaccines sales are likely to grow at a compound annual rate of 9.9% over the period 2005-2010. The human vaccines market in Asia-Pacific is projected to reach $1.3 billion by 2010.